Login

Inserisci i tuoi dati per accedere ai contenuti

RIMANI AGGIORNATO

Sulle novità dai congressi internazionali in ambito oncologico

DALL’ASCO23

Studi da conoscere

2-6 giugno 2023

Report

Addition of Olaparib and Durvalumab Prolonged Progression-Free Survival in Patients With Advanced Ovarian Cancer

Global Study Finds Simple Hysterectomy a Safe Option for People With Early-Stage, Low-Risk Cervical Cancer

Osimertinib After Surgery Significantly Improves Survival in Patients With Resected EGFR-Mutated Non-Small Cell Lung Cancer

Vorasidenib Delays Disease Progression or Death in Grade 2 Glioma With IDH Mutation

Adding Ribociclib to Hormonal Therapy Reduces Risk of Recurrence for People With Most Common Subtype of Breast Cancer

Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Cancers Regardless of Tumor Location

Radiation Treatment May Not Be Necessary After Chemoimmunotherapy for Primary Mediastinal B-cell Lymphoma

Antibody-Microtubule Inhibitor Conjugate Improves Survival in Women With Recurrent Ovarian Cancer

Adding Pembrolizumab to Chemotherapy Improves Survival in People With Advanced Cervical Cancer 

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial

Minimally Invasive Surgery Is an Effective Treatment Option for Early-Stage Pancreatic Cancer

Luspatercept Improves Anemia and Reduces Reliance on Blood Transfusions for People With Lower-risk Myelodysplastic Syndromes

Ciltacabtagene Autoleucel Reduces Risk of Disease Progression by 74% in Multiple Myeloma After Lenalidomide Stops Working

Nivolumab Reduces Risk of Disease Progression or Death in Untreated Hodgkin Lymphoma Compared to Brentuximab